NPS Logo

Press Releases

All Press Releases

2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
Date Title (click to read)
November 4, 2009 NPS Pharmaceuticals Reports Third Quarter Results and Improved Cash Burn Guidance
October 29, 2009 NPS Pharmaceuticals to Report Third Quarter Financial Results on November 4, 2009
October 26, 2009 Data Demonstrate That GATTEX(TM) (Teduglutide) Improves Lean Body Mass, Mineral Composition and Electrolyte Levels in Patients with Parenteral Nutrition Dependent Short Bowel Syndrome
October 21, 2009 NPS Reports Two Teduglutide Abstracts Accepted for Presentation at American College of Gastroenterology Annual Scientific Meeting
September 14, 2009 NPS Pharmaceuticals to Present at UBS Global Life Sciences Conference
September 3, 2009 NPS Pharmaceuticals to Present at Rodman & Renshaw Annual Healthcare Conference
August 10, 2009 NPS Pharmaceuticals to Present at Canaccord Adams Global Growth Conference
August 6, 2009 NPS Pharmaceuticals Reports Second Quarter 2009 Financial Results; Two Phase 3 Registration Programs Continue to Advance on Stated Timelines
August 6, 2009 NPS Pharmaceuticals Secures $40 Million Committed Equity Financing Facility
August 3, 2009 NPS Pharmaceuticals to Report Second Quarter Financial Results on August 6, 2009
July 24, 2009 Company Profile for NPS Pharmaceuticals
July 13, 2009 NPS Pharmaceuticals Appoints Dr. Colin Broom to Its Board of Directors
June 24, 2009 NPS Pharmaceuticals President and CEO Dr. Francois Nader Recognized By Ernst & Young as 2009 Entrepreneur of the Year Finalist in New Jersey
June 11, 2009 NPS Pharmaceuticals to Present at Jefferies Healthcare Conference
June 5, 2009 NPS Pharmaceuticals to Present at Needham Life Sciences Conference
June 3, 2009 New Findings Demonstrate Potential Benefits of GATTEX(TM) (teduglutide) in Phase 3 Study of Patients with Short Bowel Syndrome
May 28, 2009 NPS Reports Three Teduglutide Abstracts Accepted for Presentation at Digestive Disease Week Conference
May 5, 2009 NPS Pharmaceuticals Reports First Quarter 2009 Financial Results; Registration Studies Advance for Lead Product Candidates
April 28, 2009 NPS Pharmaceuticals to Report First Quarter 2009 Financial Results
March 27, 2009 NPS Pharmaceuticals to Present at Citi Biotech Day
March 13, 2009 NPS Pharmaceuticals Reports Strong 2008 Results; Phase 3 Registration Studies Underway for Two Product Candidates
March 11, 2009 NPS Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
March 5, 2009 NPS Pharmaceuticals to Present at Barclays Capital Global Healthcare Conference
March 5, 2009 NPS Pharmaceuticals to Report 2008 Financial Results
February 4, 2009 NPS Pharmaceuticals to Present at BIO CEO & Investor Conference
Date Title (click to read)
December 22, 2008 NPS Pharmaceuticals Initiates Phase 3 'REPLACE' Study of NPSP558 in Hypoparathyroidism
December 3, 2008 NPS Pharmaceuticals Appoints Roger Garceau as Chief Medical Officer
December 2, 2008 NPS Pharmaceuticals Initiates Phase 3 'STEPS' Study to Confirm GATTEX(TM) Reduces Parenteral Nutrition Dependence in Short Bowel Syndrome
November 21, 2008 NPS Pharmaceuticals to Present at Piper Jaffray Health Care Conference
November 6, 2008 NPS Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference
November 5, 2008 NPS Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
October 31, 2008 NPS Pharmaceuticals to Report Third Quarter 2008 Financial Results
October 15, 2008 NPS Pharmaceuticals Announces Multiple GATTEX(TM) Data Presentations at 16th United European Gastroenterology Week Meeting
October 8, 2008 One Year of GATTEX(TM) Therapy Safely Reduces Parenteral Nutrition Dependence for Patients with Short Bowel Syndrome
September 23, 2008 GATTEX(TM) Abstracts to be Presented at ACG Meeting; 52-Week Data from Phase 3 Clinical Trial Scheduled for Plenary Session
September 15, 2008 Positive Interim Data from Phase 2 Study of NPSP558 (Parathyroid Hormone 1-84) for Hypoparathyroidism Reported at ASBMR Annual Meeting
September 11, 2008 NPS Pharmaceuticals to Report GATTEX(TM) Data at ESPEN, ACG, UEGW Congresses
August 7, 2008 NPS Pharmaceuticals Reports Second Quarter Financial Results
July 29, 2008 NPS Pharmaceuticals to Report Second Quarter 2008 Financial Results
June 18, 2008 NPS Pharmaceuticals to Present at Jefferies Healthcare Conference
June 16, 2008 NPS Pharmaceuticals Notified of ANDA Filings for Cinacalcet HCl
May 19, 2008 Phase 3 GATTEX(TM) Results Presented at Annual Digestive Disease Week Congress Highlight Potential New Treatment in Short Bowel Syndrome
May 13, 2008 NPS Appoints Dr. Bo Joelsson as Head of Clinical Research
May 8, 2008 GATTEX(TM) Abstracts Accepted for Presentation at DDW Conference; Phase 3 Short Bowel Syndrome Results Scheduled for Oral Plenary Session
May 7, 2008 NPS Pharmaceuticals Reports First Quarter 2008 Financial Results and Business Update
April 29, 2008 NPS Pharmaceuticals to Report First Quarter 2008 Financial Results
March 17, 2008 NPS Reports Successful GATTEX(TM) Extension Study
March 13, 2008 NPS Pharmaceuticals Reports 2007 Financial Results
March 6, 2008 NPS Pharmaceuticals to Report 2007 Financial Results
February 29, 2008 NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
February 26, 2008 NPS Pharmaceuticals Announces Senior Management Changes
February 4, 2008 NPS Pharmaceuticals to Present at BIO CEO & Investor Conference
January 30, 2008 NPS Pharmaceuticals Announces Board Appointments
January 28, 2008 NPS Pharmaceuticals Provides Update on GATTEX(TM) Clinical Development in Short Bowel Syndrome
January 2, 2008 NPS Pharmaceuticals Appoints Dr. Alan G. Harris Chief Medical Officer
Date Title (click to read)
December 21, 2007 NPS Pharmaceuticals to Present at the JPMorgan 26th Annual Healthcare Conference on January 9, 2008
November 13, 2007 NPS Pharmaceuticals Announces Senior Management Appointments
November 2, 2007 NPS Pharmaceuticals to Webcast Presentation at CIBC World Markets 18th Annual Healthcare Conference
November 1, 2007 NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
October 31, 2007 Nycomed Confirms Commitment to GATTEX(TM) Partnership; NPS to Receive $25 Million Payment
October 30, 2007 NPS Pharmaceuticals Names Douglas N. Dobak Vice President of Regulatory Affairs and Drug Safety
October 25, 2007 NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
October 25, 2007 NPS Pharmaceuticals Announces Approval of Cinacalcet HCl in Japan
October 18, 2007 NPS Pharmaceuticals Announces Results of Tender Offer
October 11, 2007 Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
October 9, 2007 NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development
October 8, 2007 NPS Pharmaceuticals Names Brian O'Callaghan as New Chief Commercial Officer
October 3, 2007 NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
September 26, 2007 NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America
September 19, 2007 PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
September 6, 2007 NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008
August 7, 2007 NPS Pharmaceuticals Raises $200 Million to Retire Debt, Reports Second Quarter Financial Results and Revises Guidance
August 7, 2007 NPS Pharmaceuticals Completes $100 Million Series B Note Offering Backed by Sensipar(R) Royalties
August 7, 2007 NPS Pharmaceuticals Announces $50 Million Convertible Note Sale
July 19, 2007 NPS Announces Legal Staff Changes
July 16, 2007 NPS Pharmaceuticals Announces Sale of Preotact(R) Royalty to Drug Royalty Corporation (DRC)
July 12, 2007 NPS Pharmaceuticals to Report Second Quarter 2007 Financial Results on August 7, 2007
July 9, 2007 NPS Pharmaceuticals Expands Agreement with European Partner Nycomed to Include Broader Territory Rights for Preotact(R)
July 3, 2007 NPS Appoints Francois Nader, M.D., to Executive Vice President and COO
July 3, 2007 NPS Pharmaceuticals Announces Sale of Two Facilities
June 19, 2007 NPS Pharmaceuticals to Webcast Presentation at Jefferies Healthcare Conference
June 11, 2007 NPS Pharmaceuticals to Webcast Presentation at Goldman Sachs 28th Annual Global Healthcare Conference
June 4, 2007 NPS Announces Progression of the Calcilytics Development Program in Osteoporosis by GlaxoSmithKline
May 9, 2007 NPS Reports First Quarter 2007 Financial Results and Progress in Executing New Business Plan, Reiterates Guidance
May 3, 2007 NPS Pharmaceuticals to Report First Quarter 2007 Financial Results
April 24, 2007 NPS Pharmaceuticals to Webcast Presentation at Citigroup Global Healthcare Conference
March 14, 2007 NPS Pharmaceuticals Reports 2006 Results and Progress, Announces New Business Plan to Advance Pipeline
March 12, 2007 NPS Pharmaceuticals to Webcast Presentation at Lehman Brothers Global Healthcare Conference
February 20, 2007 NPS Pharmaceuticals to Report Fourth Quarter and Year-end Financial Results
Date Title (click to read)
November 8, 2006 NPS Pharmaceuticals Reports Third Quarter and Nine Month Results
October 13, 2006 NPS Pharmaceuticals to Report Third Quarter 2006 Financial Results
August 3, 2006 NPS Pharmaceuticals Reports Second Quarter and Six Month Operating Results
July 18, 2006 NPS Pharmaceuticals to Report Second Quarter 2006 Financial Results
July 14, 2006 NPS Pharmaceuticals Named in Securities Class Action Lawsuit
June 21, 2006 NPS Pharmaceuticals to Webcast Presentation at Jefferies Life Sciences Conference
June 12, 2006 NPS Announces Aggressive Plan to Restructure Operations and Cut Costs
June 6, 2006 NPS Pharmaceuticals to Webcast Presentation at Goldman Sachs 27th Annual Global Healthcare Conference
June 6, 2006 NPS Pharmaceuticals Appoints Francois Nader, MD, MBA, Chief Medical and Commercial Officer
May 12, 2006 NPS Elects N. Anthony Coles, M.D. Chief Executive Officer
May 11, 2006 Teduglutide Abstract Selected for Late-Breaking Session at Digestive Disease Week 2006
May 2, 2006 NPS Pharmaceuticals Reports First Quarter 2006 Operating Results
May 2, 2006 NPS Announces Clinical Advancement of Calcilytics Program by Its Collaborator GlaxoSmithKline
April 28, 2006 NPS Pharmaceuticals to Webcast Presentation at Morgan Stanley Healthcare Unplugged Conference
April 26, 2006 European Commission Issues Marketing Authorization for Preotact(R) (PREOS(R))
April 24, 2006 NPS Names Juergen Lasowski, Ph.D., Senior Vice President of Corporate Development
April 24, 2006 NPS Pharmaceuticals to Report First Quarter 2006 Financial Results
April 17, 2006 NPS Pharmaceuticals to Webcast Presentation at UBS Global Specialty Pharmaceuticals Conference
March 29, 2006 NPS Updates Status of PREOS(R) NDA
March 10, 2006 NPS Receives Approvable Letter for PREOS NDA
February 27, 2006 NPS to Advance Clinical Development of Teduglutide as Treatment for Crohn's Disease
February 23, 2006 CHMP Recommends Authorization to Market Preotact(R) (PREOS(R)) in Europe
February 16, 2006 NPS Pharmaceuticals Reports Fourth Quarter and Year-End Operating Results
February 8, 2006 NPS Announces Extension of R&D Collaboration With AstraZeneca
January 31, 2006 NPS Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results
January 25, 2006 NPS Files Shelf Registration Statement Under New SEC Rules, Retires Previous Shelf Registration Statement
January 4, 2006 NPS Pharmaceuticals to Webcast Presentation at 24th Annual JP Morgan Healthcare Conference
Date Title (click to read)
November 4, 2005 NPS Pharmaceuticals Reports Third Quarter and Nine Month Results
November 2, 2005 Event Update: NPS Pharmaceuticals to Report Third Quarter Financial Results at 10:00 a.m. EST on November 4, 2005
November 1, 2005 N. Anthony Coles, M.D., M.P.H., Joins NPS Pharmaceuticals as Chief Operating Officer and Successor to CEO Hunter Jackson, Ph.D.
October 28, 2005 NPS Pharmaceuticals to Report Third Quarter Financial Results
October 24, 2005 NPS Pharmaceuticals to Promote Allergan's RESTASIS(R) to Rheumatologists in the United States
September 27, 2005 Event Time Correction: NPS Pharmaceuticals to Webcast Investment Community Meeting at American Society for Bone and Mineral Research Conference at 11:30 Central Time Today
September 27, 2005 New Analyses Show PREOS(R) Improves Bone Strength and Reduces Fracture Risk in Postmenopausal Women With Osteoporosis
September 23, 2005 NPS Pharmaceuticals to Webcast Investment Community Meeting at American Society for Bone and Mineral Research Conference
September 8, 2005 NPS Pharmaceuticals Announces Planned Sale of Common Stock
August 23, 2005 NPS Pharmaceuticals Files Shelf Registration Statement
August 18, 2005 Medical Journal Reports Teduglutide Improves Intestinal Function in Patients With Short Bowel Syndrome
August 10, 2005 Year-Two PaTH Data Demonstrate Benefit of Sequential Therapy for Osteoporosis
July 26, 2005 NPS Pharmaceuticals Reports Second Quarter and Six Month Operating Results
July 19, 2005 NPS Pharmaceuticals to Report Second Quarter Financial Results
July 11, 2005 PREOS(R) New Drug Application Accepted for Review by FDA
May 10, 2005 NPS Pharmaceuticals Reports First Quarter 2005 Operating Results
May 3, 2005 NPS Pharmaceuticals to Report First Quarter Financial Results
April 7, 2005 New TOP Study Data Analyses of PREOS Show Improved Bone Microarchitecture and Reduction in Vertebral Fractures in Postmenopausal Osteoporotic Patients
March 30, 2005 NPS Announces Start of Preotact(TM) Regulatory Review in Europe
March 8, 2005 NPS Pharmaceuticals Reports Fourth Quarter and Year-End Operating Results
March 3, 2005 NPS Pharmaceuticals and Ventiv Health Announce the Launch of a Specialty Sales Force
March 1, 2005 NPS Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results
February 7, 2005 NPS Provides Update on PREOS(R) NDA Process and Timing
Date Title (click to read)
December 23, 2004 NPS Pharmaceuticals Announces Conference Call and Webcast to Be Held Today
December 23, 2004 NPS Completes $175 Million Note Offering Backed by Sensipar(R) Royalties
December 16, 2004 NPS Names Michael Bonney and Rachel Selisker to Its Board of Directors
November 30, 2004 NPS Preparing Expanded PREOS(R) NDA Package to Be Submitted in February 2005
November 8, 2004 NPS Pharmaceuticals Reports Third Quarter and Nine Month Results
November 8, 2004 Reminder - NPS Pharmaceuticals to Report Third Quarter and Nine Month Operating Results
November 1, 2004 NPS Pharmaceuticals to Report Third Quarter and Nine Month Operating Results
October 21, 2004 NPS Pharmaceuticals Presents Additional TOP Study Data at ACR
October 19, 2004 NPS Pharmaceuticals to Discuss Top Study Results at ACR Scientific Meeting
October 14, 2004 Reminder - NPS Pharmaceuticals Third Annual Investor/Analyst Meeting 2004
October 12, 2004 NPS Pharmaceuticals Third Annual Investor/Analyst Meeting 2004
October 11, 2004 NPS Reports Inconclusive Results of Acute Migraine Study
October 4, 2004 NPS Pharmaceuticals Announces Positive Results of Three PREOS Trials at ASBMR
September 30, 2004 NPS Pharmaceuticals to Host Meeting for the Investment Community and Webcast at the American Society of Bone and Mineral Research Conference
September 27, 2004 NPS Announces Presentation of Top Study Data at Rheumatology Meetings
August 9, 2004 NPS Pharmaceuticals Reports Second Quarter and Six Month Operating Results
August 9, 2004 NPS Pharmaceuticals to Promote Amgen's Kineret(R) to Rheumatologists
August 2, 2004 NPS Pharmaceuticals to Report Second Quarter and Six Month Operating Results
May 26, 2004 NPS Pharmaceuticals Celebrates Tenth Anniversary of IPO and Nasdaq Market Listing
May 6, 2004 NPS Pharmaceuticals Reports First Quarter 2004 Results
April 29, 2004 NPS Pharmaceuticals to Report First Quarter Financial Results
April 26, 2004 NPS Appoints Pharmaceutical Executives to Commercial Team
April 21, 2004 NPS Pharmaceuticals and Nycomed Announce US$90+ Million PREOS(R) Marketing Agreement for Europe
April 6, 2004 NPS Pharmaceuticals Begins Pivotal Study With Teduglutide in Patients With Short Bowel Syndrome
March 30, 2004 NPS Announces Positive Phase III Study Results for PREOS(R) in Women With Osteoporosis
March 29, 2004 NPS Pharmaceuticals to Host PREOS Study Results Conference Call on March 30, 2004
March 8, 2004 NPS Pharmaceuticals Announces Approval of Sensipar(TM) by U.S. FDA
February 10, 2004 NPS Pharmaceuticals Reports Fourth Quarter and Year-End Operating Results
February 10, 2004 Reminder - NPS Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results
February 3, 2004 NPS Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results
February 2, 2004 NPS Pharmaceuticals to Speak and Webcast Presentation at Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference
January 26, 2004 NPS Pharmaceuticals to Webcast Presentation At US Bancorp Piper Jaffray Healthcare Conference
January 13, 2004 NPS Pharmaceuticals to Speak and Webcast Presentation AT 22nd Annual JP Morgan Healthcare Conference
Date Title (click to read)
December 16, 2003 NPS Begins Clinical Trial in Migraine, Appoints Chief Medical Officer
November 20, 2003 NPS Reports Positive PREOS Study Results
November 19, 2003 NPS Pharmaceuticals to Report Results of PREOS Carcinogenicity Study
November 6, 2003 NPS Pharmaceuticals Reports Third Quarter and Nine Month Operating Results
October 30, 2003 NPS Pharmaceuticals to Report Third Quarter and Nine Month 2003 Financial Results
October 7, 2003 NPS Pharmaceuticals Announces Completion of Top Study Dosing, Launch of Crohn's Trial
September 20, 2003 NPS Comments on Interim Results of PaTH Study Data
September 8, 2003 NPS Pharmaceuticals Announces NDA Filing by Amgen for Cinacalcet HCL
August 12, 2003 NPS Pharmaceuticals Reports Second Quarter and Six Month Operating Results
August 5, 2003 NPS Pharmaceuticals to Report Second Quarter And Six Month 2003 Financial Results
July 22, 2003 NPS Pharmaceuticals Announces Settlement of Claim Against Forest Laboratories
July 9, 2003 NPS Pharmaceuticals Announces Exercise of Option to Purchase an Additional $22 Million of Its 3.0% Convertible Debt
June 11, 2003 NPS Pharmaceuticals Announces Pricing of $170 Million Convertible Debt Offering
June 11, 2003 NPS Pharmaceuticals Announces Proposed Convertible Debt Offering
June 4, 2003 NPS Pharmaceuticals Announces Corporate Presentations on Friday, June 6 and Thursday, June 12
June 4, 2003 NPS Pharmaceuticals and Enzon Pharmaceuticals Announce Mutual Termination of Merger Agreement
May 14, 2003 NPS Pharmaceuticals Reports First Quarter 2003 Results
May 7, 2003 NPS Pharmaceuticals To Report First Quarter 2003 Financial Results
April 23, 2003 NPS Reports Announcement of Cinacalcet HCl Data
April 9, 2003 NPS and Enzon Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Merger
March 24, 2003 NPS and Enzon File Registration Statement on Form S-4
March 11, 2003 NPS Pharmaceuticals Second Annual Investor/Analyst Meeting 2003
February 27, 2003 NPS Pharmaceuticals Reports Fourth Quarter and Year End 2002 Financial Results; Comments on Merger With Enzon
February 26, 2003 NPS Pharmaceuticals Provides Update of Progress With PREOS(TM) and Cinacalcet HCL
February 24, 2003 NPS Pharmaceuticals to Report Fourth Quarter and Year-End Operating Results
February 20, 2003 NPS Pharmaceuticals and Enzon Pharmaceuticals Agree to Merger of Equals
February 6, 2003 NPS Pharmaceuticals Provides Clinical Update
January 21, 2003 NPS Pharmaceuticals Introduces Redesigned Website
January 16, 2003 NPS Compound, PREOS(TM), Tested in Space
Date Title (click to read)
October 30, 2002 NPS Announces Conclusion of Financing, Deactivation of Shelf Registration
October 25, 2002 NPS Pharmaceuticals Prices Public Offering of Common Stock
October 21, 2002 NPS Pharmaceuticals Provides Corporate Update, Reports Third Quarter 2002 Operating Results
October 18, 2002 NPS Pharmaceuticals to File Preliminary Prospectus Supplement for 4,000,000 Share Public Offering
October 18, 2002 NPS Pharmaceuticals Revises Date to Report Third Quarter and Nine Month Operating Results
October 17, 2002 NPS Pharmaceuticals Appoints Stephen R. Parrish Vice President, Manufacturing
October 17, 2002 NPS Pharmaceuticals to Report Third Quarter and Nine Month Operating Results
September 30, 2002 NPS Completes 'Power' Study Enrollment
August 15, 2002 NPS Reports Interim PREOS Carcinogenicity Results
July 23, 2002 NPS Pharmaceuticals Reports Successful Production of PREOS, Second Quarter 2002 Operating Results
July 16, 2002 NPS Pharmaceuticals Announces Conference Call and Webcast of PREOS Manufacturing Update and Second Quarter 2002 Operating Results
July 3, 2002 NPS Pharmaceuticals Announces Appointment of Gerard Michel as Vice President, Corporate Development
June 12, 2002 NPS Pharmaceuticals Conference Call Replay Information
June 11, 2002 NPS Pharmaceuticals Announces Conference Call
June 11, 2002 NPS Update on Preos Manufacturing
June 10, 2002 NPS Pharmaceuticals to Present at Goldman, Sachs Healthcare Conference
May 20, 2002 Governor’s Medal Awards For Science And Technology Recipients Announced
May 8, 2002 NPS Pharmaceuticals Reports First Quarter 2002 Results
May 8, 2002 NPS Pharmaceuticals Announces Conference Call and Webcast Of First Quarter 2002 Operating Results
April 24, 2002 NPS Pharmaceuticals Announces Conference Call and Webcast Of First Quarter 2002 Operating Results
March 26, 2002 NPS Pharmaceuticals Reports Progress in Osteoporosis and Short Bowel Syndrome Clinical Trials
March 22, 2002 NPS Pharmaceuticals to Host Webcast on Current Research Programs In Osteoporosis, Gastrointestinal and CNS Disorders
February 5, 2002 NPS Pharmaceuticals Reports Fourth Quarter And Year End 2001 Financial Results; Clinical Program Update
February 4, 2002 NPS Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter And Full Year 2001 Operating Results
January 22, 2002 NPS Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter And Full Year 2001 Operating Results
January 7, 2002 NPS Pharmaceuticals Intends to File Shelf Registration Statement

Notice to Readers
The reports filed by NPS with the Securities and Exchange Commission and the news releases issued by NPS and posted on this website are current only as of the dates on which they were filed or issued by NPS. Therefore, the contents of these reports and releases can become outdated. We make no commitment, and disclaim any duty, to update these reports and releases. We do not warrant the accuracy or completeness of these materials or the reliability of any advice, opinion, statement or other information displayed or distributed through the website. Readers acknowledge that any reliance on these reports, releases, advice, opinions, statements, or information are at the reader's sole risk.